Treatment of hyperkalemia: From "hyper k+" strikeout to home run?

JAMA - Journal of the American Medical Association

Volumn 314, Issue 2, 2015, Pages 129-130

  Winkelmayer, Wolfgang C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; INSULIN; LOOP DIURETIC AGENT; LOSARTAN; PATIROMER; PLACEBO; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POLYMER;

BLEEDING; COMORBIDITY; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; INTESTINE NECROSIS; MORBIDITY; MORTALITY; PERFORATION; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; COMPLICATION; FEMALE; MALE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERKALEMIA; MALE; POLYMERS; POTASSIUM;

EID: 84937403625     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7521     Document Type: Short Survey

References (7)

1. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169 (12):1156-1162.
2. Miao Y, Dobre D, Heerspink HJ, et al. Increased serum potassium affects renal outcomes. Diabetologia. 2011;54(1):44-50.
3. Korgaonkar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD. Clin J AmSoc Nephrol. 2010;5(5):762-769.
4. BakrisGL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. doi: 10.1001/jama.2015.7446.
5. WeirMR, Bakris GL, Bushinsky DA, et al; OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211-221.
6. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233.
7. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222-231.